4,397 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Bought by Lbp Am Sa

LBP AM SA bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 4,397 shares of the medical research company's stock, valued at approximately $1,444,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BIO. Wealthfront Advisers LLC purchased a new stake in Bio-Rad Laboratories in the 4th quarter worth approximately $342,686,000. Point72 Asset Management L.P. purchased a new stake in Bio-Rad Laboratories in the 3rd quarter worth approximately $83,681,000. Wedge Capital Management L L P NC purchased a new stake in Bio-Rad Laboratories in the 4th quarter worth approximately $28,740,000. Mawer Investment Management Ltd. increased its holdings in Bio-Rad Laboratories by 63.0% in the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company's stock worth $72,900,000 after acquiring an additional 84,237 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in Bio-Rad Laboratories in the 4th quarter worth approximately $9,820,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO traded up $0.56 during midday trading on Thursday, reaching $254.73. 280,625 shares of the stock traded hands, compared to its average volume of 268,275. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. The stock has a market capitalization of $7.14 billion, a PE ratio of -3.92 and a beta of 0.98. Bio-Rad Laboratories, Inc. has a one year low of $244.00 and a one year high of $387.99. The company's 50 day moving average is $306.74 and its 200 day moving average is $326.40.

Remove Ads

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on BIO shares. Wells Fargo & Company reduced their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Finally, StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $395.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.